Amgen said on Monday its experimental cancer therapy significantly improved overall survival in patients with advanced ...

Newsom backtracks on return to office order for California workers amid union demands ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

The latest trading day saw Amgen (AMGN) settling at $296.85, representing a +2.18% change from its previous close.

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

Following quite encouraging news from the laboratory on Monday, Amgen (NASDAQ: AMGN) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% ...

Amgen & Zai Lab's trial shows bemarituzumab + chemo boosts survival in gastric cancer with FGFR2b. Read more here.

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in ...

Verizon Communications Inc. stands out as the top Dow dividend pick with strong cash flow and value potential. Click for my ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...